Insulin-induced glucose control improves HDL cholesterol levels but not reverse cholesterol transport in type 2 diabetic patients

Atherosclerosis. 2014 Aug;235(2):415-7. doi: 10.1016/j.atherosclerosis.2014.05.942. Epub 2014 Jun 4.

Abstract

Type 2 diabetes (T2D) is characterized by low HDL cholesterol (HDL-C) and HDL dysfunction. We herein tested whether lowering HbA1c affects HDL-C and reverse cholesterol transport (RCT). Forty-two uncontrolled T2D patients initiating basal insulin were included. HbA1c, HDL-C and RCT were assessed at baseline and after 6 months. At baseline, HDL-C and RCT were directly correlated (r = 0.50; p < 0.001). After 6 months of insulin therapy, HbA1c dropped from 8.8 ± 0.16% to 7.1 ± 0.1%, while average HDL-C and RCT did not change. Follow-up HDL-C and RCT were still correlated (r = 0.31; p = 0.033) and ΔHDL-C correlated with ΔRCT (r = 0.32; p = 0.029). ΔHbA1c correlated with ΔHDL-C (r = 0.43, p = 0.001), but not with ΔRCT. In patients with ΔHbA1c above the median value (1.3%), HDL-C (but not RCT) increased significantly. In conclusion, glucose control correlates with increased HDL-C, but not with improved RCT. Thus, persistent HDL dysfunction despite improved HbA1c and HDL-C can contribute to residual cardiovascular risk in T2D.

Trial registration: ClinicalTrials.gov NCT00699686.

Keywords: Atherosclerosis; Cardiovascular risk; Cholesterol; Diabetes; HDL.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Biological Transport / drug effects*
  • Cholesterol / metabolism*
  • Cholesterol, HDL / metabolism*
  • Diabetes Mellitus, Type 2 / drug therapy
  • Diabetes Mellitus, Type 2 / physiopathology*
  • Female
  • Glycated Hemoglobin / metabolism*
  • Humans
  • Insulin / therapeutic use*
  • Male

Substances

  • Cholesterol, HDL
  • Glycated Hemoglobin A
  • Insulin
  • hemoglobin A1c protein, human
  • Cholesterol

Associated data

  • ClinicalTrials.gov/NCT00699686